Trial · NCT03608033
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in 24-hour UPE in g/Day Compared to Baseline | OMS721 | -21.3 | Standard Error 0.0672 | Percent Change | |
| Percent Change in 24-hour UPE in g/Day Compared to Baseline | Placebo | -16.6 | Standard Error 0.0680 | Percent Change | |
| Change in Annualized eGFR Compared to Baseline. | OMS721 (High Baseline Proteinuria Group) | -8.3 | Standard Deviation 0.9 | mL/min/1.73 m²/year | |
| Change in Annualized eGFR Compared to Baseline. | Placebo (High Baseline Proteinuria Group) | -7.9 | Standard Deviation 0.9 | mL/min/1.73 m²/year | |
| Change in Annualized eGFR Compared to Baseline in All Patients. | OMS721 | -6.4 | Standard Deviation 0.7 | mL/min/1.73 m²/year | |
| Change in Annualized eGFR Compared to Baseline in All Patients. | Placebo | -7.6 | Standard Deviation 0.7 | mL/min/1.73 m²/year | |
| Change in 24-hour UPE in g/Day Compared to Baseline in All Patients | OMS721 | -14.2 | Standard Deviation 0.7 | g/ 24hrs | |
| Change in 24-hour UPE in g/Day Compared to Baseline in All Patients | Placebo | -10.3 | Standard Deviation 0.6 | g/ 24hrs | |
| Change in 24-hour UPE in g/Day Between 36 Weeks and 48 Weeks. | OMS721 (High-risk Proteinuria Group) | 4.1 | Standard Deviation 0.5 | g/24hr | |
| Change in 24-hour UPE in g/Day Between 36 Weeks and 48 Weeks. | Placebo (High-risk Proteinuria Group) | 4.4 | Standard Deviation 0.6 | g/24hr | |
| Change in 24-hour UPE in g/Day Between 36 Weeks and 72 Weeks in Patients With >= 2 g/Day UPE at Baseline (High-risk Proteinuria Group). | OMS721 (High-risk Proteinuria Group) | 11.6 | Standard Deviation 0.7 | g/24hr | |
| Change in 24-hour UPE in g/Day Between 36 Weeks and 72 Weeks in Patients With >= 2 g/Day UPE at Baseline (High-risk Proteinuria Group). | Placebo (High-risk Proteinuria Group) | 7.5 | Standard Deviation 0.8 | g/24hr | |
| Change in 24-hour UPE in g/Day Between 36 Weeks and 48 Weeks in All Patients | OMS721 | 6.2 | Standard Deviation 0.5 | g/24hr | |
| Change in 24-hour UPE in g/Day Between 36 Weeks and 48 Weeks in All Patients | Placebo | 3.5 | Standard Deviation 0.6 | g/24hr | |
| Change in 24-hour UPE in g/Day Between 36 Weeks and 72 Weeks in All Patients | OMS721 | 10.9 | Standard Deviation 0.7 | g/24hr | |
| Change in 24-hour UPE in g/Day Between 36 Weeks and 72 Weeks in All Patients | Placebo | 14.2 | Standard Deviation 0.8 | g/24hr | |
| Safety and Tolerability of Narsoplimab for the Treatment of IgAN as Assessed by AEs, Vital Signs, Clinical Laboratory Tests, and ECGs | OMS721 | 181 | Participants | ||
| Safety and Tolerability of Narsoplimab for the Treatment of IgAN as Assessed by AEs, Vital Signs, Clinical Laboratory Tests, and ECGs | Placebo | 179 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03608033/results